Revolve Wealth Partners LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Revolve Wealth Partners LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 3.1% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 3,595 shares of the biopharmaceutical company’s stock after buying an additional 108 shares during the period. Revolve Wealth Partners LLC’s holdings in Gilead Sciences were worth $399,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the 1st quarter valued at $25,000. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Core Alternative Capital lifted its holdings in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GILD. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Finally, UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $118.08.

View Our Latest Stock Report on GILD

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,000 shares of company stock worth $7,632,100. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $118.21 on Tuesday. The firm has a market cap of $146.68 billion, a PE ratio of 23.55, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The firm’s 50-day simple moving average is $114.72 and its 200-day simple moving average is $110.30. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $84.34 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.